HIV Reservoirs Cure Research – More Investments Are Needed
Antiretroviral therapy has been very successful in lengthening the diseases free periods in those who are HIV-positive; however, HIV infection persists for life, and every time therapy is stopped, the HIV rekindles and becomes active again. These HIV reservoirs of viruses must be dealt with. If left unchecked for too long, the mechanisms leading to full blown AIDS start again and severe health problems occur. Therefore, more HIV research is needed to attack these reservoirs with new medications, and that can only happen if more research and development can be put into the project. HIV suppression has worked so far, but additional research could yield a medication that targets directly the HIV latency period. We must be committed to funding additional research.
Without a preventive vaccine on the horizon, HIV’s pandemic is not controlled and could turn into something far more major and devastating. This isn’t just a problem in a few industrialized nations; HIV is a worldwide problem, and it’ll take a global effort to eradicate this terrible disease. Scientists can do their part by continuing to do research on new strategies against HIV; doctors can evaluate the effectiveness of each medication patients can continue to use these products and explain to the doctors what works and what doesn’t. Also, government agencies can make it easier for scientists by showing a real and concrete political will to cure the disease.
In addition to political and medical support, HIV research requires a fair amount of financial support. Developing new kinds of drugs takes some time and huge financial efforts, but with a global commitment, the HIV reservoirs can be dealt with in timely manner, the HIV latency period can be therapeutically targeted, which means reaching a ‘functional cure’ at least for millions of people living with HIV on a regular basis. While HIV persistence is inevitable in those who are HIV-positive, the right treatment will make it seem as if the virus is not affecting them at all, and one of the goals is to allow these HIV-positive people to lead as normal a life as they possibly can. With more time, effort, and financial support, we can also achieve a cure and total HIV eradication. However, that journey begins with a single step in the right direction.
About us: Dr. Alain Lafeuillade, Chair of the HIV Persistence and Reservoirs Workshop, Coordinator of the HIV Scientific Portal on HIV Reservoirs: http://www.hiv-reservoir.net
Dr. Alain Lafeuillade
1208 av Col. Picot. 83056
Toulon – France
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release HIV Reservoirs Cure Research – More Investments Are Needed here
News-ID: 158459 • Views: 1012
More Releases from AVPS
New Trends Towards HIV Cure Research
Fifteen years after the advent of combined antiretroviral therapy (ART) life expectancy of HIV-infected patients, as well as their quality of life, have considerably improved. However, ART remains a life long battle as these therapies are unable to eradicate the virus. Although we can still improve tolerance and acceptability of ART, the next decisive step would be to find a cure. Specific budget lines have been created in 2010 and
Approaches to HIV Eradication
The various approaches to HIV eradication all address a problem, and that problem is the HIV reservoir. HIV reservoirs have been called the last hiding place for HIV within the body. The final step toward finding a cure against HIV lies in dealing with HIV reservoirs. Toulon, France, August 30, 2011 - What can be done about HIV eradication? The advancements in scientific technology and medical treatments have made significant progress
Clues to HIV Persistence on ART
Recent research has found that while antiretroviral therapy (ART) is effective at significantly reducing the number of plasma-to-T-cell transmissions of HIV, it's not as effective against T-cell-to-T-cell. The remaining virus hides in infected T-cells, which allows it to easily be passed on to non-infected ones; this, in fact, is one of the reasons why HIV persists through ART. Toulon, France, August 23, 2011 - HIV has a built-in backup plan when
More Releases for HIV
HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: firstname.lastname@example.org or +91-11-47067990 Report Table of Contents Introduction to Human Immunodeficiency Virus (HIV) Vaccines 1.1 Overview 1.2 Antiquity of HIV Vaccine Need for the Development of HIV Vaccine Primer of HIV inside the Body 3.1 Inclusion of HIV Virus into the System 3.2 Interaction of HIV with Host 3.3 Eradication of HIV Virus HIV Vaccine Development Process 4.1 Introduction
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways
Hidden HIV Revealed: New Insights Into Latent HIV Infections
In spite of ever more effective therapies, HIV keeps managing to survive in the body. A comprehensive project conducted by the Austrian Science Fund FWF has clarified the molecular processes which contribute to this effect. In the process, approaches were discovered for possible therapies to combat the hidden reservoir formed by the virus. Thanks to modern therapies, HIV infections have become controllable – but these treatments cannot provide a cure. Antiretroviral